KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Intangibles (2016 - 2025)

Jazz Pharmaceuticals has reported Intangibles over the past 16 years, most recently at $4.4 billion for Q4 2025.

  • Quarterly Intangibles fell 6.86% to $4.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.4 billion through Dec 2025, down 6.86% year-over-year, with the annual reading at $4.4 billion for FY2025, 6.86% down from the prior year.
  • Intangibles was $4.4 billion for Q4 2025 at Jazz Pharmaceuticals, down from $4.6 billion in the prior quarter.
  • Over five years, Intangibles peaked at $7.6 billion in Q2 2021 and troughed at $1.0 million in Q3 2021.
  • The 5-year median for Intangibles is $5.2 billion (2024), against an average of $4.9 billion.
  • Biggest five-year swings in Intangibles: tumbled 99.96% in 2021 and later soared 556939.4% in 2022.
  • Tracing JAZZ's Intangibles over 5 years: stood at $7.2 billion in 2021, then fell by 18.99% to $5.8 billion in 2022, then tumbled by 87.01% to $752.5 million in 2023, then surged by 531.99% to $4.8 billion in 2024, then decreased by 6.86% to $4.4 billion in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $4.4 billion, $4.6 billion, and $4.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.